You are here

  • Home
  • Archive
  • Volume 9, Issue 9
  • Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates

 

Online download statistics by month:

Online download statistics by month: September 2021 to April 2023

AbstractFullPdf
Sep 2021507507160
Oct 202124824990
Nov 202114214264
Dec 202110010024
Jan 202211111955
Feb 2022687136
Mar 2022697144
Apr 2022858737
May 2022989933
Jun 2022839546
Jul 2022596221
Aug 2022707232
Sep 2022819361
Oct 2022687330
Nov 2022606033
Dec 2022353616
Jan 2023424444
Feb 2023818234
Mar 2023282915
Apr 2023293121
Total20642122896